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BACKGROUND: Pralatrexate is a dihydrofolate reductase (DHFR) inhibitor with high affinity for reduced folate carrier 1 (RFC-1) and
folylpolyglutamate synthetase (FPGS), resulting in extensive internalization and accumulation in tumour cells. Pralatrexate is approved
in the US for the treatment of relapsed or refractory peripheral T-cell lymphoma and is being investigated in various malignancies.
Here, we evaluated molecular correlates of sensitivity to pralatrexate and explored combinations with a variety of anticancer agents.
METHODS: Antiproliferative effects of pralatrexate were evaluated in 15 human-cancer cell lines using the MTT assay. Gene expression
was evaluated using qRT–PCR.
RESULTS: Pralatrexate and methotrexate had a similar pattern of cytotoxicity, pralatrexate being more potent. Pralatrexate potentiated
the effects of platinum drugs, antimetabolites and EGFR inhibitors. Dose- and time-dependent cytotoxicity of pralatrexate correlated
with high mRNA expression of FPGS. Acquired resistance to pralatrexate was associated with decreased RFC-1 expression, whereas
methotrexate resistance correlated with increased DHFR expression, suggesting different mechanisms of acquired resistance.
CONCLUSION: Pralatrexate was more potent than methotrexate in a panel of solid tumour lines. Our findings support the further
clinical development of pralatrexate in combination with certain cytotoxics and targeted therapies, and suggest that RFC-1, FPGS and
DHFR may be potential biomarkers of outcome.
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The folate pathway has a key role in cell growth and proliferation
(Appling, 1991; Odin et al, 2003). Folic acid (folate) enters cells
through reduced folate carrier 1 (RFC-1), is polyglutamated by
folylpolyglutamate synthetase (FPGS), and is reduced to dihydro-
folate, which is further converted to tetrahydrofolate (THF) by
dihydrofolate reductase (DHFR). The different enzymes and
transporters involved in this pathway are targets for an important
class of cytotoxic agents, antifolates. Methotrexate was one of the
first agents of this class and was first used in the treatment of
childhood acute lymphoblastic leukaemia (Farber et al, 1948).
Since then, methotrexate has been widely used in haematologic
and solid cancers, and new generations of antifolates have been
rationally designed to exploit multiple aspects of the folate
pathway (e.g., raltitrexed in colorectal cancer (Cocconi et al,
1998), and pemetrexed in malignant pleural mesotheliomas
(Vogelzang et al, 2003) and non-small-cell lung carcinomas
(NSCLC) (Hanna et al, 2004)).
Pralatrexate ((RS)-10-propargyl-10-deazaaminopterin) is a syn-
thetic anti-DHFR antifolate, rationally designed to have greater
affinity for RFC-1 and FPGS, resulting in increased cytotoxic
activity as compared with methotrexate (DeGraw et al, 1993;
Sirotnak et al, 1998). The cytotoxicity of pralatrexate was shown to
be correlated with RFC-1 mRNA expression in human lymphoma
cells (Wang et al, 2003).
Pralatrexate is undergoing clinical evaluation as a single agent or
in combination in several tumour types, including lymphoma
(O’Connor et al, 2007; Marneros et al, 2009), and has received
accelerated approval by the US Food and Drug Administration
(FDA) for patients with refractory or relapsed peripheral T-cell
lymphoma.
In this study, we have compared the antiproliferative activity of
pralatrexate with that of methotrexate and other antimetabolites in
several human solid tumour cell lines. In addition, we further
evaluated molecular mechanisms of action of pralatrexate, and
screened for markers of sensitivity and acquired resistance to
pralatrexate, knowledge of which could be of potential use for
designing future clinical trials. Finally, possible sequence-depen-
dent synergy or additive effects of pralatrexate with various
cytotoxic and targeted agents were also investigated.
MATERIALS AND METHODS
Cell lines
A panel of colon (HT29, HCT116, COLO205 and HCC2998), breast
(MCF7), melanoma (MDA-MB-435, formerly designated as a
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sbreast cancer line), NSCLC (HOP62 (adenocarcinoma) and HOP92
(large cell carcinoma)), ovarian (OVCAR3, IGROV1), prostate
(DU145, PC3) and head and neck (SCC61, HEP2 and SQ20B)
cancer cell lines was purchased from the ATCC (Rockville, MD,
USA) and National Cancer Institute collections. Cells were grown
as monolayers in RPMI medium supplemented with 10% fetal
calf serum (Invitrogen, Cergy-Pontoise, France), 2mM glutamine,
100 Uml
 1 penicillin and 100mMml
 1 streptomycin. In this
study, we used unpurified media potentially containing glycine,
hypoxanthine and thymidine, which may have theoretically
reduced drug activity. However, considering the high levels of
resistance developed in our cell lines and taking into account that
both parental and derived resistant counterpart were grown in
similar media, it remains unlikely that this would have severely
impact on data.
Cytotoxicity assays
Cell viability was determined using the MTT assay, which was
carried out as described previously (Hansen et al, 1989). Briefly,
cells were seeded in 96-well plates at a density of 2 10
3 cells
per well. Cells were incubated for 120h and then 0.4mgml
 1 of
MTT dye (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide; Sigma, Saint-Quentin Fallavier, France), was added for
4h at 371C. Media was removed and the monolayer suspended in
0.1ml of DMSO, after which the absorbance at 560nm was
measured using a microplate reader (Thermo, Saint-Herblain,
France). The control value corresponding to untreated cells was
defined as 100% and the viability of treated samples was expressed
as a percentage of the control. IC50 values were determined as
concentrations that reduced cell viability by 50%.
For single agent studies, cells were treated with increasing
concentrations of pralatrexate, methotrexate, pemetrexed, 5-FU
and 50-DFUR for up to 72h. Then, the cells were allowed to recover
in compound-free medium for 48h before determination of growth
inhibition using the MTT assay.
For combination studies of pralatrexate with other anticancer
drugs, sequential (pralatrexate for 24h, followed by the second
agent for 24h or the inverse schedule) or simultaneous (exposure
to both agents for 24h) schedules were used. Cells were treated
with various concentrations of the drugs and the combinations.
Growth inhibition was then determined by the MTT assay.
Statistical analysis and determination of synergistic
activity
Drug combination effects were determined using the Chou and
Talalay method (Chou and Talalay, 1984) based on the median
effect principle. Combination index (CI) values of o1 indicate
synergy, a CI value of 1 indicates additive effects and a CI value
of 41 indicates antagonism. Data were analysed using the
concentration-effect analysis software (Biosoft, Cambridge, UK).
For statistical analysis and graphs, the Instat and Prism software
(GraphPad, San Diego, CA, USA) were used. Experiments were
performed three times, in duplicate. Means and standard
deviations were compared using the Student’s t-test (two-sided
P-value).
Cell cycle analysis and apoptosis
The cell cycle stage and percentage of apoptotic cells were assessed
by flow cytometry. In brief, cells were treated with various
concentrations of pralatrexate, fixed in 70% ethanol and stored at
 201C until use. Cells were rehydrated in PBS, incubated for
30min at 371C with 250mgml
 1 RNAse A and 20min at 41C with
50mgml
 1 propidium iodide in the dark. The cell cycle distri-
bution and percentage of apoptotic cells were determined with
a FACScan flow cytometer and analyzed by FACS Calibur
(Becton Dickinson, Le Pont de Claix, France). Apoptosis induction
was evaluated using an Annexin V-FITC Apoptosis Detection Kit
(BD Biosciences, Le Pont de Claix, France).
Gene expression analysis by RT–PCR
The theoretical and practical aspects of quantitative real-time PCR
(qRT–PCR) using the ABI Prism 7900 Sequence Detection System
(Perkin-Elmer Applied Biosystems, Foster City, CA, USA) have
been described in detail elsewhere (Bie `che et al, 2001). Results
were expressed as fold differences in target gene expression
relative to the TBP gene (an endogenous RNA control) and relative
to a calibrator (1  sample), consisting of the cell line sample from
our tested series that contained the smallest amount of target gene
mRNA. Experiments were performed in duplicate.
Western blot analysis
Cells were lysed in buffer containing 50mM HEPES (pH 7.6),
150mM NaCl, 1% Triton X-100, 2mM sodium vanadate, 100mM
NaF and 0.4mgml
 1 phenylmethylsulfonyl fluoride. Equal
amounts of protein (20–50mg per lane) were subjected to SDS–
PAGE and transferred to nitrocellulose membranes. Membranes
were probed with anti-cleaved PARP, anti-cleaved caspase 3,
anti-caspase 9 (Cell Signaling, Saint Quentin Yvelines, France),
anti-DHFR (Abcam, Paris, France), anti-b-actin (Sigma-Aldrich,
Saint-Quentin Fallavier, France)-specific primary antibodies,
followed by peroxidase-linked secondary antibodies and visualisa-
tion by chemiluminescence.
RESULTS
Single-agent antiproliferative effects
The antiproliferative effects of pralatrexate were examined in 15
cancer cell lines as displayed in Table 1. Time course experiments
showed that optimal antiproliferative effects were achieved when
cells were exposed to pralatrexate for 72h (Figure 1A). Pralatrexate
IC50 values ranged from 0.01±0.002mM for the prostate cancer cell
line PC3 to 4350mM for the MDA-MB-435 cell line. Interestingly,
two groups of cell lines with more than 100-fold difference in IC50
were observed: One group including PC3, SCC61, DU145, HT29,
Table 1 Cytotoxicity (IC50 values, mM) following 72h exposure to
pralatrexate, methotrexate, 5-FU, 50-DFUR or pemetrexed in a panel of
human carcinoma cell lines
Cell line
a Pralatrexate Methotrexate Pemetrexed 5-FU 50-DFUR
PC3 0.01 0.1 2.7 1.5 25
SCC61 0.011 0.03 0.015 1.2 3.2
DU145 0.015 0.3 0.048 7 28
HT29 0.02 0.22 0.023 3 16
HOP62 0.023 0.15 0.029 78 380
SQ20B 0.03 0.26 0.025 10 27
HOP92 0.031 0.6 0.02 18 135
HEP2 0.05 0.25 0.1 86 250
IGROV1 0.08 0.33 300 8 29
COLO205 9 30 0.024 0.8 3.9
HCC2998 100 4350 1.5 10 34
MCF7 200 300 0.022 1.3 7.8
HCT116 280 4350 350 10 45
OVCAR3 4350 4350 0.025 31 230
MDA435 4350 4350 300 5 33
aCell lines used: colon (HT29, HCT116, COLO205 and HCC2998), breast (MCF7),
melanoma (MDA-MB-435, formerly designated as a breast cancer line), NSCLC
(HOP62 and HOP92), ovarian (OVCAR3 and IGROV1), prostate (DU145 and
PC3), and head and neck (SCC61, HEP2 and SQ20B).
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o0.1mM, whereas Colo205, HCC2998, MCF7, HCT116, OVCAR3
and MDA-MB-435 cells showed IC50 values X9mM.
The antiproliferative effects of pralatrexate were compared with
those of methotrexate and several commonly used antimetabolites
such as pemetrexed, 5-FU and 50-DFUR, the active capecitabine
metabolite (Figure 1B and Table 1). Pralatrexate IC50 values were
on average almost 10-fold lower than those observed for
methotrexate. The cytotoxicity profiles of these two antifolates
were similar with the same distinct groups of sensitive and
resistant cell lines. The cytotoxicity profile of pralatrexate was
different from that of 5-FU, 50-DFUR and pemetrexed, suggesting
differences in the metabolism, mechanism of action and/or resis-
tance between pralatrexate and other antimetabolites. Interest-
ingly, limited cross-sensitivity was observed between pralatrexate
and pemetrexed, an antifolate, believed to be primarily a
thymidylate synthetase (TS) inhibitor.
Effect of pralatrexate and methotrexate on cell cycle
changes and apoptosis
The prostate cancer cell line DU 145 was selected as a sensitive
model to both pralatrexate and methotrexate for further investiga-
tion in this study. Cells were incubated with concentrations of
0.1mM (IC50) and 0.2mM (two-fold IC50) of pralatrexate and
0.6mM (IC50) and 1.2mM (two-fold IC50) of methotrexate for 24h.
Cell cycle analysis showed that pralatrexate-treated cells had
decreased proportions of cells in S and G2/M phases with an
increase of sub-G1 fraction (4eight-fold), suggesting apoptosis
induction (Figure 2A). A similar pattern, albeit less pronounced,
was observed in methotrexate-treated cells (Figure 2A). Thus, both
agents caused the accumulation in the G0/G1 phase and possible
apoptosis induction.
Annexin V/PI double staining showed that apoptosis increased
2.6- and 4-fold in DU145 cells at concentrations of 0.1 and 0.2mM
pralatrexate, respectively. Similar results, with 1.5- and 2-fold
increase in apoptosis, were observed in DU145 cells treated with
0.6 and 1.2mM methotrexate, respectively, again showing superior
activity of pralatrexate compared with methotrexate. Apoptosis
induction by pralatrexate was further confirmed by increases in
cleaved PARP and caspases observed after 24h exposure to
pralatrexate (see Figure 2C). From these experiments it appears
that apoptosis is the major mechanism of cancer cell death induced
by pralatrexate in this model.
Expression of genes involved in folate transport and
metabolism
The expression of genes known to be involved in sensitivity to
antifolates was analyzed in the panel of cancer cell lines. DHFR,
FPGS, TS/TYMS, thymidylate synthetase, SCL19A1/RFC-1, GARFT
(glycinamide ribonucleotide formyl transferase), SLC25A32
(mitochondrial folate transporter/carrier) and ABC transporter
B1 (ABCB1 or MDR1) mRNA expression was determined by
qRT–PCR (Figure 3A). The cell lines expressed various levels of
these folate pathway genes but no significant correlation was found
between sensitivity to pralatrexate and mRNA expression of
TS, SCL19A1/RFC-1, GARFT, SLC25A32 and MDR1. Pralatrexate-
sensitive cells expressed relatively higher levels of DHFR, a target
of pralatrexate, than the ‘resistant’ group, but this did not reach
statistical significance (P¼0.083, Figure 3A). Pralatrexate-sensitive
cells expressed significantly higher levels of FPGS mRNA than
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Figure 1 Pralatrexate cytotoxicity in a panel of human cancer cell lines. (A) Pralatrexate (PDX) time-course (IC50 values, 1, 5, 24 and 72h drug exposure)
cytotoxicity in sensitive cell lines. (B) Comparative analysis of 72h cytotoxicity of pralatrexate, methotrexate, pemetrexed, 5-FU and 50-DFUR in a panel of
cancer cell lines. The indicated values are calculated as follows: log (IC50 individual cell line) – mean (log IC50). Negative values indicate that the cell line is
more sensitive than the average, whereas positive values indicate that the cell line is more resistant than the average.
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sresistant cells (t-test, P¼0.002). Overall, a trend towards a positive
correlation between FPGS mRNA expression and pralatrexate
sensitivity (IC50 values) was found (R
2¼0.47, Po0.01), suggesting
an important role of polyglutamation in pralatrexate anti-
proliferative activity.
To determine the potential role of folate transporters in
pralatrexate activity, we correlated the IC50 values obtained after
72h drug exposure with the level of mRNA expression of
SCL19A1/RFC-1 and SLC25A32 in the nine pralatrexate-sensitive
cell lines (Figure 3B). Cells that expressed a high level of SCL19A1/
RFC-1 and SLC25A32 mRNA displayed higher sensitivity to
pralatrexate, suggesting potential roles of SCL19A1/RFC-1 and
SLC25A32 in cellular uptake of pralatrexate.
Development of pralatrexate and methotrexate resistant
cell lines
To characterize potential mechanisms of resistance to pralatrexate,
the cell lines DU-PDX and HEP-PDX were developed from parental
DU145 and HEP2 cells, respectively, by exposure to increasing
concentrations of pralatrexate over a period of 6 months. DU-PDX
and HEP-PDX cells were at least 200- and 500-fold less sensitive to
pralatrexate than parental cells (Figure 4A). After five passages in
drug-free medium, the resistant cells retained their drug resis-
tance, suggesting stability of these cell lines. As shown in
Figure 4A, pralatrexate-resistant cell lines showed partial cross-
resistance to methotrexate.
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resistance, methotrexate-resistant cell lines DU-MTX and HEP-
MTX were developed. DU-MTX and HEP-MTX displayed cross-
resistance to pralatrexate, however, the activity of pralatrexate still
remained superior (approximately 10-fold lower IC50) to that of
methotrexate (Data not shown).
Genetic changes associated with acquired pralatrexate
resistance
To determine possible mechanisms of anti-folate resistance, we
evaluated the mRNA expression of several folate genes in parental
and resistant cells. As shown in Figure 4B, mRNA expression of
DHFR, TS and SLC25A32 was not significantly changed in
pralatrexate-resistant cells. A slight decrease in FPGS mRNA
expression was observed in DU-PDX and HEP-PDX cells compared
with their parental counterparts. In contrast, SCL19A1/RFC-1
mRNA expression was 410-fold decreased in the two pralatrex-
ate-resistant cell lines. mRNA level of ABCB1/MDR1 was 40- and
2-fold higher in DU-PDX and HEP-PDX, respectively, compared
with DU145 and HEP2. These data suggest an important role of
transporters in pralatrexate antiproliferative activity and acquired
resistance. To study the role of MDR1 in pralatrexate resistance,
DU-PDX and HEP-PDX cells were incubated with 30mM verapamil,
a competitive substrate of MDR1, and 3mM cyclosporin A
concomitantly with pralatrexate for 72h. No changes were observed
in pralatrexate cytotoxicity with and without verapamil and
cyclosporine A, suggesting that MDR1 overexpression may not have
a major role in acquired resistance to pralatrexate in these cell lines.
Analysis of expression of DHFR, a target of pralatrexate and
methotrexate, showed significant increases in mRNA (more that
30-fold), as well as 410-fold increases in DNA gene copy numbers.
DHFR protein expression in HEP-MTX cells was consistently
higher compared with parental HEP2 cells (Figure 4C), suggesting
that DHFR amplification has an important role in resistance to
methotrexate (Figure 4C). Slight increase of DHFR expression in
DU-PDX and HEP-PDX was nonsignificant as compared with that
in parental DU145 and HEP2 cells (P¼0.083). This suggested that
the molecular mechanism of acquired resistance to pralatrexate in
HEP-PDX cells might differ from acquired methotrexate resistance
in HEP-MTX cells.
Analysis of cross-resistance to other antifolates and
antimetabolites
To evaluate the cross-resistance of pralatrexate-resistant cells to
other drugs, DU145, DU-PDX, HEP2 and HEP-PDX cells were
exposed to pemetrexed and 5-FU for 72h. No significant difference
between parental and PDX-resistant cells was observed for 5-FU
cytotoxicity. Pemetrexed exposure for 72h was only slightly less
cytotoxic in DU-PDX and HEP-PDX cells compared with their
parental counterparts (data not shown). These data suggest that
acquired resistance to pralatrexate may not translate into
resistance to pemetrexed and 5-FU, possibly because of the
differences in mechanism of action of these compounds.
Combination of pralatrexate with anticancer drugs
The effects of sequential and simultaneous exposure of combina-
tions of pralatrexate with oxaliplatin, cisplatin, 5-FU, 50-DFUR,
SN38, paclitaxel, gemcitabine, erlotinib or lapatinib were evaluated
in DU145 cells (Table 2).
The combination of pralatrexate with oxaliplatin or cisplatin
resulted in synergistic effects (CIo1) when drugs were given
simultaneously irrespective of the concentrations used. Pralatrex-
ate given before oxaliplatin demonstrated only additive effects and
was synergistic with cisplatin for the same administration
schedule. Administration of either of the platinum drugs before
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spralatrexate was not beneficial. Thus, the effects of pralatrexate
in combination with platinum drugs appear to be schedule
dependent.
The combination of pralatrexate with the antimetabolites 5-FU
or 50-DFUR resulted in synergistic effects for the sequential
administration schedules and appears to be antagonistic when the
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cell lines. (C) Western blot of DHFR protein in DU145 and HEP2 sensitive and DU-PDX, DU-MTX, HEP-PDX and HEP-MTX pralatrexate and
methotrexate-resistant cell lines.
Pralatrexate activity in cancer cells
M Serova et al
277
British Journal of Cancer (2011) 104(2), 272–280 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sdrugs were administered simultaneously. Combination of prala-
trexate with SN38 (the active metabolite of irinotecan) in DU145
cells resulted in synergistic effects for all schedules of administra-
tion. The combination of pralatrexate with paclitaxel resulted in
some synergistic effects for the sequential administration schedule
when paclitaxel was given before pralatrexate and additive/
antagonistic for the reverse sequence and simultaneous exposure.
The combinations of pralatrexate with erlotinib or lapatinib were
shown to be synergistic when pralatrexate was given first or
simultaneously with these EGFR kinase inhibitors, suggesting a
role of EGFR signalling in response to pralatrexate.
DISCUSSION
Pralatrexate is an antifolate with high affinity for the reduced folate
carrier 1 (RFC-1) protein and folylpolyglutamate synthetase
(FPGS), resulting in extensive internalization and accumulation
within tumour cells. Pralatrexate is currently being investigated as
a single agent and in combinations in various malignancies. In
order to guide further clinical development, molecular correlates
of sensitivity to pralatrexate and preclinical data on combination
treatments are needed.
Pralatrexate displayed potent antiproliferative activity
(IC50 o0.1mM) in 9 out of the 15 human solid-tumour cell lines.
Two distinct groups of cell lines were identified with 4100-fold
difference in pralatrexate IC50 values: sensitive and relatively
resistant cell lines. The in vitro antiproliferative effects of
pralatrexate in terms of IC50 values were on average almost
10-fold better than those observed with methotrexate. When
comparing the cytotoxic activity of these two similar antifolates to
other antimetabolites including 5-FU, 50-DFUR and pemetrexed,
pralatrexate appears to retain activity in several cells that were
poorly sensitive to 5-FU and 50-DFUR, such as NSCLC HOP62 and
HOP92 cell lines. Similarly, the sensitivity profile for pemetrexed
was different from that for pralatrexate, which may be explained
by the differences in molecular mechanism of action of these
compounds.
Izbicka et al (2009) have shown that pralatrexate demonstrated
unique attributes relative to methotrexate and pemetrexed.
Pralatrexate exhibited enhanced cellular uptake and increased
polyglutamation, which correlated with increased tumour-growth
inhibition in a NSCLC xenograft model. A positive correlation
between pralatrexate sensitivity and mRNA expression of FPGS, a
major enzyme responsible for polyglutamation of antifolates, was
found in the 15 cancer cell lines, suggesting an important role of
polyglutamation in cellular response to pralatrexate. It was shown
(Chabner et al, 1985) that if drug exposure is limited to brief
periods (24h or less), cell lines that do not form polyglutamates
efficiently are insensitive to antifolate drugs. These short exposure
conditions approximate clinical chemotherapy exposure and
emphasize the importance of rapid production of the polygluta-
mated metabolites for cytotoxicity. Continuous exposure to drug
may diminish the importance of polyglutamation. In our study,
short (1 and 5h) pralatrexate exposure induced pronounced
antiproliferative effects and these effects may be due to improved
pralatrexate cellular uptake and polyglutamation by FPGS. Cellular
uptake is likely dependent on expression of folate carriers such as
RFC-1 and SLC25A32. Although a positive correlation between
pralatrexate sensitivity and mRNA expression of FPGS, was found
in the panel of 15 cancer cell lines, only a slight but nonsignificant
decrease in FPGS mRNA expression was observed in DU-PDX and
HEP-PDX cells with acquired resistance to pralatrexate compared
with their parental counterparts suggesting that polyglutamation
may not be regarded as a main predictive factor of pralatrexate
activity .
To better elucidate the predictive genetic factors of pralatrexate
sensitivity, two cell lines with acquired resistance to the drug were
developed from DU145 (prostate) and HEP2 (head and neck)
cancer cell lines. Being more than 200-fold more resistant to
pralatrexate than parental cells, DU-PDX and HEP-PDX displayed
partial cross-resistance to methotrexate. Pralatrexate acquired
resistance was associated with decreased RFC-1 expression and
increased MDR1 expression. Fotoohi et al (2009) described
antifolate-resistant leukaemia lines with mRNA levels of RFC-1
downregulated more than two-fold in methotrexate-resistant cells,
emphasizing the important role of inux transport in antifolate
resistance. Similar data were previously obtained by Jansen and
Pieters (1998), Rothem et al (2004), and Ifergan et al (2003) using
other methotrexate-resistant cellular models. Increased MDR1
expression does not appear to have a role in the observed acquired
resistance to pralatrexate as inhibition of MDR1 did not restore
sensitivity to pralatrexate. Decreased FPGS activity was shown to
be associated with acquired resistance to methotrexate in human
leukaemia CCRF-CEM cells (Mauritz et al, 2002). In our study,
Table 2 Effects of combinations of pralatrexate with other anticancer
drugs in DU145 prostate carcinoma cells
Combination index
Combination with median (95% confidence interval)
Oxaliplatin
Pralatrexate–oxaliplatin 1.03 (0.66–1.54)
Oxaliplatin–pralatrexate 1.61 (1.33–2.19)
Pralatrexateþoxaliplatin 0.66 (0.61–0.74)
Cisplatin
Pralatrexate–cisplatin 0.66 (0.50–1.10)
Cisplatin–pralatrexate 1.12 (1.00–1.34)
Pralatrexateþcisplatin 0.68 (0.42–1.28)
5-FU
Pralatrexate–5-FU 0.81 (0.58–1.19)
5-FU–pralatrexate 0.87 (0.69–1.80)
Pralatrexateþ5-FU 1.21 (0.78–1.53)
50-DFUR
Pralatrexate–50-DFUR 0.69 (0.52–1.26)
50-DFUR–pralatrexate 0.638 (0.40–1.02)
Pralatrexateþ50-DFUR 2.20 (1.42–4.21)
SN38
Pralatrexate–SN38 0.36 (0.21–0.74)
SN38–pralatrexate 0.58 (0.45–0.76)
PralatrexateþSN38 0.76 (0.53–0.99)
Paclitaxel
Pralatrexate–paclitaxel 1.18 (0.86–2.02)
Paclitaxel–pralatrexate 0.75 (0.59–0.81)
Pralatrexateþpaclitaxel 1.33 (1.02–1.62)
Gemcitabine
Pralatrexate–gemcitabine 0.96 (0.56–1.34)
Gemcitabine–pralatrexate 1.01 (0.47–1.42)
Pralatrexateþgemcitabine 0.68 (0.16–1.13)
Erlotinib
Pralatrexate–erlotinib 0.29 (0.12–0.90)
Erlotinib–pralatrexate 0.89 (0.72–1.28)
Pralatrexateþerlotinib 0.77 (0.67–0.88)
Lapatinib
Pralatrexate–lapatinib 0.81 (0.62–1.23)
Lapatinib–pralatrexate 0.92 (0.73–1.47)
Pralatrexateþlapatinib 0.59 (0.30–0.94)
Medians (95% confidence interval) of combination index were calculated from two
independent experiments. Combination index (CI) o1 indicates synergy, CI 41
antagonism, whereas a CI equal to 1 corresponds to an additive effect.
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sa slight decrease in FPGS expression was observed in pralatrexate-
resistant cells, suggestive of a role for polyglutamation in
resistance to pralatrexate. Studies performed three decades ago
discovered that another frequent mechanism of acquired metho-
trexate resistance is DHFR gene amplification and the consequent
enzyme overexpression (reviewed by Chen et al, 1995; Assaraf,
2007). Indeed, in our study, the cell line HEP-MTX, with acquired
resistance to methotrexate, displayed a dramatic increase in DHFR
mRNA and protein expression as compared with its parental
counterpart. Increased DHFR expression was not observed in the
pralatrexate-resistant cell lines. Although differences were not
statistically significant, pralatrexate-sensitive cells expressed
relatively higher levels of DHFR, a putative target of pralatrexate,
than resistant cells. These data suggest that expression of DHFR
may not be a major factor in pralatrexate sensitivity. These
findings suggest different molecular mechanisms of resistance to
methotrexate and pralatrexate in these cell lines.
The value of antifolates as anticancer treatments is potentiated
by their use in drug combinations. A study of pralatrexate
administration in combination with gemcitabine in a panel of
lymphoma cell lines demonstrated not only that this combination
is synergistic and more efficient than methotrexate/gemcitabine in
generating apoptosis but also that the effects were highly sequence
dependent (Toner et al, 2006). Pralatrexate has also been
administered in combination with taxanes in a phase-I clinical
trial, resulting in significant antitumour activity (Azzoli et al,
2007). To provide further insight into the potential clinical use of
pralatrexate in patients with cancer, we combined pralatrexate
with several classical anticancer drugs including cisplatin,
oxaliplatin, 5-FU, 50-DFUR, gemcitabine, paclitaxel, SN38 and the
EGFR tyrosine kinase inhibitors erlotinib and lapatinib. Pralatrex-
ate demonstrated synergistic effects with several anticancer agents
and these effects were schedule dependent. Highly synergistic
effects were observed by Toner, when pralatrexate was adminis-
tered before gemcitabine in lymphoma models (Toner et al, 2006).
In our experiments, simultaneous exposure to pralatrexate with
gemcitabine was one of the best schedules. However, these results
may be model dependent. Interestingly, our results also displayed
synergistic antiproliferative effects when pralatrexate was given
before or simultaneously with the EGFR inhibitor erlotinib, or the
dual EGFR/HER2 inhibitor lapatinib.
In summary, pralatrexate was shown to be more potent than
other antifolates in a panel of solid tumour models. Several genetic
factors including RFC-1, FPGS and DHFR may be regarded as
predictive factors of pralatrexate activity in solid tumour cells.
Pralatrexate showed synergistic cytotoxic activity with several
classical cytotoxic agents as well as with targeted EGFR inhibitors
in the DU-145 prostate cancer line, and further investigation in
clinical trials is warranted.
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